



A RETROSPECTIVE STUDY OF SERUM MAGNESIUM IN TYPE 2 DIABETES MELLITUS AND CORRELATION WITH STRATEGY OF TREATMENT

*Rekha choudhary, Ramesh Chandra Thanna, Amrita Vamne & Swati Pathak

Index medical college hospital & research centre, Indore, M.P, India

Adress: 155, badnagar road, khachrod, dist-Ujjain, M.P, 4566224

*Corresponding author's e mail: mr.ramesh.thanna1111@gmail.com

ABSTRACT

Diabetes mellitus is a metabolic disease which is caused by absolute or relative insulin deficiency. About 10% of the Indian population suffers from this disease. Various factors play a role in the aetiopathogenesis and in the glycaemic control among the type 2 diabetic patients. Hypomagnesaemia has been reported to occur with increased frequency in patients with type 2 diabetes mellitus. The present study was conducted with an objective to evaluate the serum magnesium and fasting blood glucose in type 2 Diabetes mellitus cases and compare them with controls. This study also attempted to evaluate the possible relationship between the modality of treatment and serum magnesium levels. A total of 50 patients with type 2 Diabetes mellitus were recruited from the institute's medicine department. Age and sex matched apparently healthy 50 individuals with normal plasma glucose and with no symptoms suggestive of diabetes mellitus were taken as controls. Both cases and controls were subjected to estimation of biochemical parameters. There is significant difference between levels of serum magnesium levels among diabetics and controls. The mean serum magnesium levels in cases and controls are 1.80 mg/dl and 2.5 mg/dl respectively ($p < 0.001$). The mean serum magnesium levels in the oral hypoglycaemic (OHA) group, insulin group and the insulin + OHA group were 2.3 mg/dl, 1.7mg/dl and 1.25 mg/dl respectively. There is significantly low level of serum magnesium in Type 2 DM. The serum magnesium levels were also significantly lower in insulin treated group compared to the OHA group.

KEY WORDS: Hypomagnesemia, Diabetes Mellitus, Insulin, Oral Hypoglycaemic Agents (OHA).

INTRODUCTION

Type 2 diabetes mellitus is metabolic and endocrinological disease characterised by hyperglycemia associated with insulin resistance and/or defective insulin secretion^[1]. Type-2 DM is a state of chronic systemic inflammation and it has been found to increase the insulin resistance. Type-2 DM was found to be associated with an increase in the levels of the tumour necrosis factor- α and β , the C reactive protein, the plasminogen activator inhibitor-1 (PAI-1), and interleukin-6 (IL-6). The increase in these inflammatory mediators may precede and even predict the development of type-2 DM^[2]. In addition to hyperosmolar coma and ketoacidosis, patients with type 2 diabetes mellitus may have cardiovascular disease, nephropathy, retinopathy and polyneuropathy^[3]. Magnesium is the fourth most abundant cation in the human body and the second most abundant intracellular cation^[4]. It plays an important role in the carbohydrate metabolism. It serves as a cofactor for all enzymatic reactions that require kinases^[5]. It is also an essential enzyme activator for neuromuscular excitability and cell permeability, a regulator of ion channels and mitochondrial function, a critical element in cellular proliferation and apoptosis, and an important factor in both cellular and humoral functions^[6]. The treatment of the patients of type 2 diabetes mellitus requires a multidisciplinary approach, whereby every potential complicating factor must be closely monitored

and treated. In particular, although hypomagnesaemia has been reported to occur with increased frequency in patients with type 2 diabetes mellitus, it is frequently overlooked and undertreated^[7]. The present study was conducted with an objective to evaluate the serum magnesium and fasting blood glucose in type 2 Diabetes mellitus cases and compare them with controls. Very few studies have evaluated the relationship between serum magnesium and modality of treatment in type 2 diabetes mellitus. The present study also attempts to evaluate the possible relationship between the modality of treatment and serum magnesium levels.

MATERIALS & METHODS

A total of 50 patients with type 2 diabetes mellitus were recruited from the medicine department of index medical college, indoor, M.P., India from January to August 2014 after obtaining written informed consent. The diagnosis of type 2 diabetes mellitus was confirmed by biochemical investigations as per WHO criteria^[8]. Age and sex matched apparently healthy 50 individuals with normal plasma glucose, and with no symptoms suggestive of DM, were taken as controls. Patients with acute or chronic diarrheal/ malabsorption states, with thyroid or adrenal dysfunction, history of alcohol intake, history of vitamin or mineral supplements in the recent past, recent metabolic acidosis, pregnancy, lactation, with serum creatinine > 1.5

mg/dl, and on drugs known to affect magnesium levels, were excluded from the study^[9]. Both cases and controls were subjected to estimation of biochemical parameters. Fasting plasma glucose was estimated by using commercially available kit (GOD-POD method) in automated analyzer. Magnesium was estimated by a kit that uses calmagite dye method^[10]. The reference serum magnesium level by this method was 1.6-2.5 mg/dl. Data obtained are analysed statistically by using online student t-test calculator. Student t test was used to find the significance of mean pattern of serum magnesium between cases/controls and Insulin/OHA.

RESULTS

A Comparative study consisting of 50 Diabetes mellitus patients and 50 controls was undertaken to investigate the change pattern of serum magnesium in DM cases when compared to controls. The mean age of the diabetics was 56.12±12.65 years, whereas in control, it was 55.23 ±12.84 years. Both among the cases and controls, the sex distribution was same *i.e.* 65% males and 35% females. The maximum number of patients was in the age group of 41-50 *i.e.* 42%. The mean FBS levels among cases and controls were 242 mg/dl and 97.26 mg/dl respectively.

TABLE 1: effect of DM on serum magnesium

Group	Number of Subjects(N)	Average S. Magnesium level (mg/dl)(Mean ± SD)	P-value
Case	50	1.80 ± 0.47	0.0001
Control	50	2.5 ± 0.31	

TABLE 2: Comparison of S. magnesium between case and control

S. Magnesium level (mg/dl)	Case(n)	Control(n)
<1	02(4%)	0
1-1.5	15(30%)	03(6%)
1.5-2	24(48%)	35(70%)
2-2.5	08(16%)	09(18%)
>2.5	01(2%)	03(6%)
	Total(n):50	Total(n):50

TABLE 3: Effect of type of treatment on serum magnesium

Type of Treatment	Number(n)	S. magnesium (mg/dl) (Mean ± SD)	P-value
Insulin	33	1.7 ± 0.23	0.0001
OHA	17	2.3 ± 0.45	

There was significant difference between levels of serum magnesium among diabetics and controls. The mean serum magnesium levels in cases and controls were 1.80 mg/dl and 2.5 mg/dl respectively ($p < 0.001$). Out of the total of 50 diabetic patients, 23 (45%) were on insulin alone, 17 (34%) were on OHA'S and 10(21%) were on combination of OHA'S and insulin. The mean serum magnesium levels in the OHA group, insulin group and the insulin + OHA group were 2.3 mg/dl, 1.7 mg/dl and 1.25 mg/dl respectively. The serum magnesium levels were significantly lower in the insulin treated group compared to the OHA treated group. Infections were the most common cause for admission – accounting for 54% of the admissions among diabetics. The next commonest cause for admission was cardiovascular disease, which accounted for 16% of the admissions. Out of these, 50% were on insulin, 37.5% on OHA's and 12.5% on OHA's and insulin both. Out of the cardiovascular disease patients, 3 were admitted for stable angina, 3 for unstable angina and 2 for myocardial infarction. Neurological problems accounted for 12% of admissions. 4 patients admitted for stroke, 1 for cranial nerve palsy, and 1 for peripheral neuropathy. Peripheral vascular disease accounted 12% of admissions. 4 patients had ischemic signs in the limbs and 2 patients had gangrene. 6% of patients were admitted exclusively for poorly controlled diabetes.

DISCUSSION

Of all the endocrine and metabolic disorders associated with magnesium deficiency, diabetes mellitus is the most common. Many studies have shown that plasma levels of magnesium are lower in patients with type 1 and type 2 diabetes mellitus, compared to non-diabetic control subjects. Inverse correlations between magnesium and fasting plasma glucose/ HbA1C/ HOMA-IR have been observed^[11,12]. Factors implicated in hypomagnesemia in diabetics include diets low in magnesium^[13] osmotic diuresis causing high renal excretion of magnesium, insensitivity to insulin affecting intracellular magnesium transport, and thereby causing increased loss of the extracellular magnesium^[14] rampant use of loop and thiazides diuretics promoting magnesium wasting^[15,16], diabetic autonomic neuropathies^[4] and reduced tubular reabsorption due to insulin resistance^[17]. Sometimes frequent use of antibiotics and antifungals such as aminoglycosides and amphotericin in patients with diabetes may also contribute to renal magnesium wasting^[18]. Hypomagnesemia may be a contributing factor for the long term complications, particularly ischemic heart disease^[19], retinopathy^[20,21], foot ulcer^[22] and peripheral neuropathy^[23]. In our study, there was significant decrease in serum magnesium level in type 2 DM as compared to controls. Similar decrease in serum magnesium level in diabetic patients as compared to controls has been reported

in other studies^[23]. Our study also demonstrated that serum magnesium levels were significantly lower in patients on insulin treatment, compared to patients who were on oral hypoglycaemic agents alone.

CONCLUSION

Hypomagnesemia, defined herein as having low serum magnesium concentrations, is common among patients with type 2 diabetes. Contributory mechanisms are multifactorial. As available data suggest that adverse outcomes are associated with hypomagnesemia, it is prudent that routine surveillance for hypomagnesemia is done, and the condition be treated whenever required. A magnesium rich diet consisting of whole grains legumes, fruits and vegetables, such as spinach, okra and dry apricots, may be recommended. Further studies on the role of magnesium supplementation in type 2 DM in the Indian population are recommended.

REFERENCES

- [1]. Sarkar, A., Dash, S., Barik, B.K., Muttigi, M.S., Kedage, V., Shetty, J.K. (2010) Copper and Ceruloplasmin levels in relation to total thiols and GST in type 2 diabetes mellitus patients. *Ind j Clin Biochem.* 25:74-6.
- [2]. Ketan Mangukiya & Neha Sharma (2014) Clinical Correlation between diabetes mellitus type 2 and vitamin D3 (25 OH cholecalciferol) level. *I.J.S.N.*, Vol. 5 (3): 440-442.
- [3]. Pham, P.C., Pham, P.M., Pham, S.V., Miller, J.M., Pham, P.T. (2007) Hypomagnesemia in patients with type 2 diabetes. *Clin J Am Soc Nephrol*, 2:366- 73.
- [4]. Saris, N.E.L., Mervaala, E., Karppanen, H., Khawaja, J.A., Lewenstam, A. (2000) Magnesium: An update on physiological, clinical and analytical aspects. *Clin Chem Acta*; 294:1–26.
- [5]. Elamin, A., Tuvemo, T. (1990) Magnesium and insulin-dependent diabetes mellitus. *Diabetes Res Clin Pract*; 10:203–9.
- [6]. Kao, W.H.L., Folsom, A.R., Nieto, F.J., MO, J.P., Watson, R.L., Brancati, F.L. (1999) Serum and dietary magnesium and the risk for type 2 diabetes: The Atherosclerosis Risk in Communities Study. *Arch Intern Med*; 159 :2151-59.
- [7]. Diabetes mellitus. Report of a WHO Study Group. *World Health Organ Tech Rep Ser* 1985; 727:1-113.
- [8]. Dasgupta, A., Sarma, D., Saikia, U.K. (2012) Hypomagnesemia in type 2 diabetes mellitus. *Indian J Endocrinol Metab*; 16:1000-3.
- [9]. Hua, H., Gonzales, J., Rude, R.K. (1995) Magnesium transport induced ex vivo by a pharmacological dose of insulin is impaired in non-insulin-dependent diabetes mellitus. *Magnes Res*; 8:359-66.
- [10]. Kim, D.J., Xun, P., Liu, K., Loria, C., Yokota, K. Jacobs. (2010) Magnesium intake in relation to systemic inflammation, insulin resistance, and the incidence of diabetes. *Diabetes Care*; 33:2604-10.
- [11]. Limaye, C.S., Londhey, V.A., Nadkar, M.Y., Borges, N.E. (2011) Hypomagnesemia in critically ill medical patients. *J Assoc physicians India*; 59:19- 22.
- [12]. Schulze, M.B., Schultz, M., Heidemann, C., Schienkiewitz, A., Hoffmann, K., Boeing, H. (2007) Fiber and magnesium intake and incidence of type 2 diabetes: A prospective study and meta-analysis. *Arch Intern Med*; 167:956-65.
- [13]. Paolisso, G., Sgambato, S., Passariello, N., Giugliano, D., Scheen, A., D'Onofrio, F. (1986) Insulin induces opposite changes in plasma and erythrocyte magnesium concentrations in normal man. *Diabetologia*; 29:644-7.
- [14]. Nijenhuis, T., Renkema, K.Y., Hoenderop, J.G., Bindels, R.J. (2006) Acid- base status determines the renal expression of Ca²⁺ and Mg²⁺ transport proteins. *J Am Soc Nephrol*; 17:617–26.
- [15]. Duarte, C.G. (1968) Effects of chlorothiazide and amipramizide (MK 870) on the renal excretion of calcium, phosphate and magnesium. *Metabolism*; 17:420–9.
- [16]. Barbagallo, M., Dominguez, L.J. (2007) Magnesium metabolism in type 2 diabetes mellitus, metabolic syndrome and insulin resistance. *Arch Biochem Biophys*; 458:40-7.
- [17]. Pham, P.C., Pham, P.M., Pham, P.A., Pham, S.V., Pham, H.V., Miller, J.M. (2005) Lower serum magnesium levels are associated with more rapid decline of renal function in patients with diabetes mellitus type 2. *Clin Nephrol*; 63:429–36.
- [18]. Nadler, J.L., Buchanan, T., Natarajan, R., Antonipillai, I., Bergman, R., Rude, R. (1993) Magnesium deficiency produces insulin resistance and increased thromboxane synthesis. *Hypertension*; 21:1024-9.
- [19]. Ceriello, A., Guigliano, D., Dello Russo, P., Passariello, N. (1980) Hypomagnesaemia in relation to diabetic retinopathy. *Diabetes Care*; 5:558-9.
- [20]. Kareem, I., Jaweed, S.A., Bardapurkar, J.S., Patil, V.P. (2004) Study of Magnesium, Glycosylated hemoglobin and lipid profile in diabetic retinopathy. *Indian J Clin Biochem*; 19:124–7.
- [21]. Guerrero-Romero, F., Rodriguez-Moran, M. (2006) Hypomagnesemia, oxidative stress, inflammation, and metabolic syndrome. *Diabetes Metab Res Rev*; 22:471-6.
- [22]. De Lorde Lima, M., Cruz, T., Pousada, J.C., Rodrigues, L.E., Barbosa, K., Canguçu, V. (1998) The effect of magnesium supplementation in increasing doses on the control of type 2 diabetes. *Diabetes Care*; 21:682- 6.
- [23]. Supriya, Mohanty, S., Murgod, R., Pinnelli, V.B.K., Raghavendra, D.S. (2012) Hypomagnesemia, Lipid profile and Glycosylated haemoglobin in type 2 Diabetes mellitus patients. *International Journal of Chemical and Pharmaceutical Research*; 1:116-23.